INT163283

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.71
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 21
Total Number 21
Disease Relevance 3.77
Pain Relevance 2.26

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (E2F1) nucleoplasm (E2F1) mitochondrion (E2F1)
nucleus (E2F1) DNA binding (E2F1) transcription factor binding (E2F1)
Anatomy Link Frequency
H69 4
HeLa 1
E2F1 (Homo sapiens)
Pain Link Frequency Relevance Heat
qutenza 650 99.92 Very High Very High Very High
cINOD 3 66.08 Quite High
metalloproteinase 1 44.64 Quite Low
addiction 1 13.20 Low Low
Inflammation 18 5.00 Very Low Very Low Very Low
Central nervous system 13 5.00 Very Low Very Low Very Low
cytokine 13 5.00 Very Low Very Low Very Low
ischemia 13 5.00 Very Low Very Low Very Low
Gabapentin 13 5.00 Very Low Very Low Very Low
aspirin 7 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Small Cell Lung Cancer 315 99.86 Very High Very High Very High
Lymphatic System Cancer 3 99.04 Very High Very High Very High
Repression 18 95.92 Very High Very High Very High
Cancer 469 90.92 High High
Metastasis 52 80.04 Quite High
Lung Cancer 63 76.72 Quite High
Colon Cancer 13 75.00 Quite High
Apoptosis 58 67.84 Quite High
Chronic Lymphoid Leukemia 8 49.04 Quite Low
Non-small-cell Lung Cancer 10 41.04 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
To figure out whether endogenous E2F1 could still have some influence on TSP1 promoter activity, we knocked down the expression of endogenous E2F-1 by an E2F1-specific short interfering RNA (siRNA) vector into U2OS cells.
Gene_expression (expression) of E2F-1
1) Confidence 0.71 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0 Pain Relevance 0
The expression of Flag-tagged wild-type E2F-1 and the mutant (E132) were verified by Western blot (Fig. 2G) using anti-Flag antibody.
Gene_expression (expression) of E2F-1
2) Confidence 0.71 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0 Pain Relevance 0
Here, we presented data to show that pRB1 could also suppress E2F-1's transactivity on TSP1 promoter in a dose-dependent manner, which is consistent with the role of pRB1 in modulating expression of E2F-1 targets, further confirming that TSP1 serves as a bona fide target of E2F-1.
Gene_expression (expression) of E2F-1
3) Confidence 0.71 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0.62 Pain Relevance 0
The expression of different function domains of E2F1 were verified by Western blot (Fig. 2J).
Gene_expression (expression) of E2F1
4) Confidence 0.71 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0 Pain Relevance 0
As shown in Fig. 1C, the TSP-1 promoter activity was steadily up-regulated along with increasing amounts of E2F1 expression vector.
Gene_expression (expression) of E2F1
5) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0.08 Pain Relevance 0
The results indicted that E2F-1 response elements were located in the region between ?
Gene_expression (response) of E2F-1
6) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0 Pain Relevance 0
At the same time, different function domains of E2F1 were cloned into Flag-tagged vector and co-transfected into 293 cells with TSP1 promoter luciferase reporter TSP1(?
Gene_expression (transfected) of E2F1
7) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0 Pain Relevance 0
To figure out whether endogenous E2F1 could still have some influence on TSP1 promoter activity, we knocked down the expression of endogenous E2F-1 by an E2F1-specific short interfering RNA (siRNA) vector into U2OS cells.
Gene_expression (expression) of E2F1
8) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0 Pain Relevance 0
These results not only further confirmed the up-regulation of TSP-1 by E2F-1 effectively, but also ruled out the non-specific up-regulation of TSP-1 promoter activity as a result of ectopic expression of large amount of E2F-1 expression vector.
Gene_expression (expression) of E2F-1
9) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0.07 Pain Relevance 0
Flag empty vector or different dose of Flag-tagged E2F-1 expression vector, TSP1(?
Gene_expression (expression) of E2F-1
10) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0.09 Pain Relevance 0
In consistence with up-regulation of TSP-1 activity by over-expression of E2F-1, the knockdown of endogenous E2F-1 inhibited TSP-1 promoter activity significantly, implying that E2F-1 mediated regulation of TSP-1 is relevant in vivo.
Gene_expression (expression) of E2F-1
11) Confidence 0.61 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2955548 Disease Relevance 0.16 Pain Relevance 0
Total RNA was extracted from 293 cells 24h after transfected by either HA-E2F1 expression vector or equivalent control empty vector.
Gene_expression (expression) of E2F1
12) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0 Pain Relevance 0
Then, we did dose response experiments for E2F-1 overexpression on TSP1 promoter activity.
Gene_expression (overexpression) of E2F-1
13) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0.10 Pain Relevance 0
It was found that the expression of E2F1 was negatively regulated by miR-17-5p and miR-20a in HeLa cells.
Gene_expression (expression) of E2F1 in HeLa
14) Confidence 0.51 Published 2007 Journal Mol Cancer Section Body Doc Link PMC2098778 Disease Relevance 0.84 Pain Relevance 0
Treatment with lovastatin or celecoxib decreased the levels of cyclin D1, CDK2, pRb and E2F1, while the combination treatment showed more pronounced suppression.
Gene_expression (levels) of E2F1
15) Confidence 0.49 Published 2009 Journal Int. J. Oncol. Section Abstract Doc Link 19787257 Disease Relevance 0.33 Pain Relevance 0.07
E2F1, E2F2, E2F3, E2F4, E2F5 and E2F6 siRNAs were individually transfected in H69 cells.
Gene_expression (transfected) of E2F1 in H69
16) Confidence 0.44 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2857654 Disease Relevance 0.59 Pain Relevance 0.82
Western blotting analysis showed that the transfection of the above mentioned siRNAs suppressed E2F1–6 protein levels in both H69 and DMS114 cells (Fig. 4, B and C, respectively).
Gene_expression (levels) of E2F1 in H69
17) Confidence 0.44 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2857654 Disease Relevance 0.08 Pain Relevance 0.61
E2F1–6-siRNAs were individually transfected in H69 cells using Oligofectamine reagent.
Gene_expression (transfected) of E2F1 in H69
18) Confidence 0.44 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2857654 Disease Relevance 0.23 Pain Relevance 0.45
Control H69 SCLC cells contained E2F1, E2F2 and E2F3 bound to proliferative promoters.
Gene_expression (contained) of E2F1 in H69 associated with small cell lung cancer
19) Confidence 0.38 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2857654 Disease Relevance 0.57 Pain Relevance 0.30
Chemically synthesized, double-stranded siRNA for E2F1, E2F2, E2F3, E2F4, E2F5 and E2F6 was purchased from Santa Cruz Biotechnology.
Gene_expression (synthesized) of E2F1
20) Confidence 0.34 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2857654 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox